| Name | INH6 |
| Description | INH6, an effective Hec1 inhibitor, selectively disrupts the Hec1/Nek2 interaction and induces chromosome mis-alignment. |
| Cell Research | Standard XTT assays with a four-day drug treatment procedure are performed to measure the dose-dependent cytotoxicity of INH analogs in cultured cells. Triplicate sets are measured and compiled for final data presentation. The assay is performed by using a commercial kit following the instructions. In principle, cells are plated on 96-well dishes one day before the drug treatment, followed by drug treatment on day 2 and XTT assay on day 5 after drug addition. The absorption at 595 nm is measured with a plate reader and converted to cell survival percentages in comparison to mock treated groups.(Only for Reference) |
| In vitro | INH6 effectively targets the Hec1/Nek2 complex for degradation, and shows potent cell killing activity with IC50 of 1.7, 2.1, 2.4, and 2.5 μM in MDA-MB231, MDA-MB468, HeLa and K562 cell lines. INH6 also triggers mitotic abnormalities in HeLa cells, and induces apoptosis. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : 9 mg/mL (27.9 mM)
H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 60 mg/mL (186.1 mM)
|
| Keywords | Apoptosis | INH6 | Inhibitor | INH 6 | inhibit | INH-6 |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Acetylcysteine | Kaempferol | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Metronidazole | Sorafenib | Tributyrin | Lidocaine hydrochloride |
| Related Compound Libraries | Apoptosis Compound Library | Bioactive Compound Library | Microtubule-Targeted Compound Library | Inhibitor Library | NO PAINS Compound Library | PPI Inhibitor Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library |
United States
